Longboard Pharmaceuticals, Inc., (LBPH): Price and Financial Metrics


Longboard Pharmaceuticals, Inc., (LBPH): $4.26

-0.14 (-3.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LBPH to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LBPH Stock Price Chart Interactive Chart >

Price chart for LBPH

LBPH Price/Volume Stats

Current price $4.26 52-week high $6.47
Prev. close $4.40 52-week low $2.70
Day low $4.18 Volume 41,736
Day high $4.38 Avg. volume 26,092
50-day MA $4.70 Dividend yield N/A
200-day MA $4.17 Market Cap 57.88M

Longboard Pharmaceuticals, Inc., (LBPH) Company Bio


Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.


LBPH Latest News Stream


Event/Time News Detail
Loading, please wait...

LBPH Latest Social Stream


Loading social stream, please wait...

View Full LBPH Social Stream

Latest LBPH News From Around the Web

Below are the latest news stories about LONGBOARD PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LBPH as an investment opportunity.

Longboard Pharmaceuticals Announces Positive Topline Data from a Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers

LA JOLLA, Calif., December 05, 2022--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline results from a Phase 1 clinical study evaluating the central nervous system (CNS) pharmacokinetics (PK) and pharmacodynamics (PD) of LP352, an oral, centrally acting 5-HT2C superagonist, in healthy volunteers.

Yahoo | December 5, 2022

Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present data for LP352, a novel, highly selective investigational treatment in development for seizures associated with a range of developmental and epileptic encephalopathies (DEEs), in two poster

Wallstreet:Online | November 29, 2022

Longboard Pharmaceuticals: Arena''s Next Act Flying Under Radar

Longboard Pharmaceuticals is a Buy. Key concerns include near term dilution, binary risk as a single drug story and low trading volume. Read my analysis on LBPH.

Seeking Alpha | November 23, 2022

Longboard Pharmaceuticals to Present at Guggenheim’s Healthcare Talks 4th Annual Immunology and Neurology Day

LA JOLLA, Calif., November 08, 2022--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present in a fireside chat format at the Guggenheim Healthcare Talks 4th Annual Immunology and Neurology Day, which is taking place November 14-15, 2022, in New York City.

Yahoo | November 8, 2022

Longboard Pharmaceuticals: Q3 Earnings Insights

Longboard Pharmaceuticals (NASDAQ: LBPH ) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:30 AM. Here''s what investors need to know about the announcement. Earnings Longboard Pharmaceuticals missed estimated earnings by 6.25%, reporting an EPS of … Full story available on Benzinga.com

Benzinga | November 3, 2022

Read More 'LBPH' Stories Here

LBPH Price Returns

1-mo 30.67%
3-mo 12.70%
6-mo 20.34%
1-year 1.43%
3-year N/A
5-year N/A
YTD 30.67%
2022 -33.20%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6382 seconds.